IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,82 -0,85 (-1,02%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
58.741,91 +3.443,92 (+6,23%)
Minerva Neurosciences, Inc. (NERV)
Después del cierre:
Minerva Neurosciences, Inc.
1500 District Avenue
Burlington, MA 01803
United States
617 600 7373
https://www.minervaneurosciences.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 9
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Remy Luthringer Ph.D. | Executive Chairman & CEO | 1,27M | N/A | 1961 |
| Mr. Geoffrey Robin Race F.C.M.A., M.B.A. | President | 913,3k | N/A | 1961 |
| Mr. Joseph Reilly | Senior VP & COO | 461k | N/A | 1975 |
| Mr. William B. Boni | Vice President of Investor Relations & Corporate Communications | N/A | N/A | 1952 |
| Prof. Michael Davidson M.D. | Chief Medical Officer | 657,47k | N/A | 1950 |
Descripción
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Gobierno corporativo
El ISS Governance QualityScore de Minerva Neurosciences, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
